Sökning: id:"swepub:oai:DiVA.org:uu-280189" >
Evaluation of the p...
Evaluation of the protein biomarkers and the analgesic response to systemic methylene blue in patients with refractory neuropathic pain : a double blind, controlled study
-
- Miclescu, Adriana, 1958- (författare)
- Uppsala universitet,Anestesiologi och intensivvård
-
- Svanh, Martin (författare)
- Uppsala universitet,Avdelningen för farmakognosi
-
- Gordh, Torsten (författare)
- Uppsala universitet,Anestesiologi och intensivvård
-
(creator_code:org_t)
- 2015
- 2015
- Engelska.
-
Ingår i: Journal of Pain Research. - 1178-7090. ; 8, s. 387-397
- Relaterad länk:
-
https://uu.diva-port... (primary) (Raw object)
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.2...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Aim: This study was carried out in patients with neuropathic pain in order to assess the analgesic effects and changes in protein biomarkers after the administration of methylene blue (MB), a diaminophenothiazine with antioxidant and anti-inflammatory properties, and with inhibitory effects on nitric oxide.Materials and methods: Ten patients with chronic refractory neuropathic pain were randomized to receive either MB (10 mg/mL Methylthioninium chloride) 2 mg/kg (MB group) or MB 0.02 mg/kg (control group) infused over 60 minutes. Sensory function and pain (Numerical Rating Scale) were evaluated at baseline and at 60 minutes after the start of the infusion. The patients kept a pain diary during the next 24 hours and for the following 4 days. Plasma and urinary concentrations of 8-isoprostane-prostaglandin F2α (8-iso-PGF2α) and plasma protein biomarkers prior to and after the infusions were measured with radioimmunoassay and with proximity extension assay.Results:A decrease of the Numerical Rating Scale at 60 minutes in comparison with baseline was observed in the MB (P=0.047) group. The decrease was significant between the MB and the control group on the day of and day after MB infusion (P=0.04 and P=0.008, respectively). There was no difference in systemic protein expressions between groups except for prolactin (PRL) (P=0.02). Three patients demonstrated diminished dynamic mechanical allodynia.Conclusion:MB decreased the pain levels in patients with chronic therapy-resistant neuropathic pain on the first 2 days after administration. Known as an endocrine modulator on the anterior pituitary gland, MB infusion produced a decrease of PRL. The detailed role of PRL effects in chronic neuropathic pain remains undetermined.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Anestesi och intensivvård (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Anesthesiology and Intensive Care (hsv//eng)
Nyckelord
- Anaesthesiology and Intensive Care
- Anestesiologi och intensivvård
- methylene blue; nitric oxide; neuropathic pain
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas